U.S. markets closed

RadNet, Inc. (RDNT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
20.57-0.43 (-2.05%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close21.00
Bid19.05 x 800
Ask20.62 x 800
Day's Range20.34 - 21.02
52 Week Range5.81 - 23.45
Avg. Volume203,904
Market Cap1.062B
Beta (5Y Monthly)1.52
PE Ratio (TTM)N/A
EPS (TTM)-0.21
Earnings DateMar 10, 2021 - Mar 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-23% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • RadNet’s DeepHealth Artificial Intelligence Subsidiary Demonstrates Earlier Breast Cancer Detection in New Study

    RadNet’s DeepHealth Artificial Intelligence Subsidiary Demonstrates Earlier Breast Cancer Detection in New Study

    AI Finds Cancer Earlier DeepHealth's AI identifies cancer in a patient one year earlier than detected in practice.CAMBRIDGE, Mass. and LOS ANGELES, Jan. 11, 2021 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) today reported that its DeepHealth subsidiary, a leading developer of artificial intelligence (AI) for mammography interpretation, published results of its novel AI algorithms in Nature Medicine, illustrating an ability to detect breast cancer a year or more earlier than current practice. DeepHealth compared its AI to five full-time, breast-fellowship-trained expert radiologists reading the same screening mammograms. The software exhibited higher performance than all five radiologists, and the results suggest that the AI could help detect cancer one to two years earlier than standard interpretation in many cases. Additionally, the software showed promising generalization capabilities, demonstrating strong performance when tested across clinical sites and populations that were not directly involved in training the AI algorithms.While AI holds tremendous promise for improving screening mammography interpretation, there remain substantial challenges in developing expert-level AI. “Reaching world-class performance requires a new way of building AI,” said Gregory Sorensen, M.D., CEO, and co-founder of DeepHealth. “The brute-force methods that have worked so well in other domains, such as self-driving cars or game playing, where data is plentiful, have not translated effectively to many parts of medicine, where human data is often scarce. For example, to train the technology for better detection, AI algorithms must be developed from annotated data where the cancer status is known. Such data can be difficult to obtain. Then, to validate performance, the AI should be tested across different clinical sites and patient populations in different scenarios.”The new study by DeepHealth demonstrates progress in resolving these challenges. “We have developed an approach that mimics how humans often learn by progressively training the AI models on more difficult tasks. By leveraging prior information learned in each successive training stage, this strategy results in AI that detects cancer accurately while also relying less on highly-annotated data,” said lead author Bill Lotter, Ph.D., CTO, and co-founder of DeepHealth. “Our approach and validation extend to 3D mammography, which is particularly important given its growing use and the significant challenges it presents for AI.”“Our results point to the clinical utility of AI for mammography in facilitating earlier breast cancer detection,” Lotter noted, “as well as an ability to develop AI with similar benefits for other medical imaging applications. By building AI software with high performance and generalizability, DeepHealth has the potential to help radiologists enable more widespread access to high quality care.”DeepHealth’s first AI-based product, a software package for prioritization of 2D and 3D mammograms, is based on the same core technology described in the Nature Medicine publication. This product was submitted to the FDA in late 2020, with approval anticipated in 2021.Link to Nature Medicine paper: https://www.nature.com/articles/s41591-020-01174-9About RadNet, Inc. RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 334 owned and/or operated outpatient imaging centers. RadNet’s core markets include California, Maryland, Delaware, New Jersey, Arizona, and New York. In addition, RadNet provides radiology information technology solutions and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has approximately 8,600 employees. For more information, visit www.radnet.com.About DeepHealth, Inc. DeepHealth, a wholly owned subsidiary of RadNet, Inc., uses machine learning to distill lifetimes of insights from medical experts into software to assist physicians. DeepHealth’s mission is to enable the best care by providing products that clinicians and patients can trust, through rigorous science and clinical integration. For more information, visit www.deep.health.CONTACTS: DeepHealth, Inc. Bret Baird Chief Commercial Officer 424-832-1480 bbaird@deep.healthRadNet, Inc. Mark Stolper Executive Vice President and Chief Financial Officer 310-445-2800A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ab4a5a9c-3905-4def-84aa-a15d60c43640

  • RadNet, Inc. (NASDAQ:RDNT) Shares Could Be 33% Above Their Intrinsic Value Estimate
    Simply Wall St.

    RadNet, Inc. (NASDAQ:RDNT) Shares Could Be 33% Above Their Intrinsic Value Estimate

    Does the December share price for RadNet, Inc. ( NASDAQ:RDNT ) reflect what it's really worth? Today, we will estimate...

  • Is RDNT A Good Stock To Buy Now?
    Insider Monkey

    Is RDNT A Good Stock To Buy Now?

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]